Phase 3 Prostate Cancer Trial, Recruiting (NCT06825091)

Phase 3 Prostate Cancer Trial, Recruiting NCT06825091 Sponsor: University Health Network, Toronto Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06825091 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are over 18 years old
People who have been diagnosed with prostate adenocarcinoma (a specific type of prostate cancer confirmed by a tissue sample)
People whose prostate cancer has not spread beyond the prostate (localized cancer)
People whose cancer falls into the low, intermediate, or high risk category
People whose treatment plan includes a type of focused radiation therapy for the prostate called SBRT (a course of a small number of high-dose radiation treatments)

Who may not be able to join:

People whose treatment plan includes radiation to the nearby lymph nodes in addition to the prostate
People who have medical reasons that mean radiation therapy is not safe for them
People who have had both hips replaced, as current adaptive radiation treatment technology is not compatible with bilateral hip replacements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 416-946-4559

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06825091

Sponsor: University Health Network, Toronto

Phase: Phase 3

Status: Recruiting

Condition: Prostate Cancer

Trial contact: 416-946-4559

More information: https://clinicaltrials.gov/study/NCT06825091

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are over 18 years old
People who have been diagnosed with prostate adenocarcinoma (a specific type of prostate cancer confirmed by a tissue sample)
People whose prostate cancer has not spread beyond the prostate (localized cancer)
People whose cancer falls into the low, intermediate, or high risk category
People whose treatment plan includes a type of focused radiation therapy for the prostate called SBRT (a course of a small number of high-dose radiation treatments)

Who may not be able to join:

People whose treatment plan includes radiation to the nearby lymph nodes in addition to the prostate
People who have medical reasons that mean radiation therapy is not safe for them
People who have had both hips replaced, as current adaptive radiation treatment technology is not compatible with bilateral hip replacements

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

University Health Network, Toronto

Registry

ClinicalTrials.gov

Start date

4 February 2025

Est. completion

4 February 2030

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

To determine whether adaptive SBRT can significantly reduce the proportion of patients experiencing a minimal clinically important difference in patient reported urinary domain changes when compared to the non adaptive image guided SBRT group.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov